Uriel Sandkovsky
Overview
Explore the profile of Uriel Sandkovsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
2271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mourad A, Grandits G, Siegel L, Engen N, Barkauskas C, Eriobu N, et al.
Clin Microbiol Infect
. 2025 Feb;
PMID: 39922466
Objectives: Passive immunotherapy, including monoclonal antibodies and neutralizing proteins, was used for the treatment of patients with COVID-19 during the pandemic. Accelerating COVID-19 Therapeutic Interventions and Vaccines-Therapeutics for Inpatients with...
2.
Reilly C, Mylonakis E, Dewar R, Young B, Nordwall J, Bhagani S, et al.
J Infect Dis
. 2024 Sep;
PMID: 39269490
Background: Biomarker guided therapy could improve management of COVID-19 inpatients. Although some results indicate that antibody tests are prognostic, little is known about patient management using point-of-care (POC) antibody tests....
3.
Aggarwal N, Nordwall J, Braun D, Chung L, Coslet J, Der T, et al.
Clin Infect Dis
. 2024 Feb;
78(6):1490-1503.
PMID: 38376212
Background: Persistent mortality in adults hospitalized due to acute COVID-19 justifies pursuit of disease mechanisms and potential therapies. The aim was to evaluate which virus and host response factors were...
4.
Sloan B, Duhaime E, Sandkovsky U
Proc (Bayl Univ Med Cent)
. 2024 Jan;
37(1):151-153.
PMID: 38174027
, a commensal gram-positive rod, is an emerging cause of human disease in individuals with multiple comorbidities and in immunocompromised patient populations. New microbiologic laboratory tests including molecular diagnostics with...
5.
Karnatak R, Sandkovsky U
Cureus
. 2023 Aug;
15(7):e41412.
PMID: 37546149
Methods: We retrospectively reviewed all the patients who underwent new continuous-flow (C-F) LVAD implantation between January 1, 2013, and December 31, 2014, at the University of Nebraska Medical Center. Patients...
6.
Kataria V, Berhe M, Sandkovsky U
Proc (Bayl Univ Med Cent)
. 2022 Aug;
35(5):655-657.
PMID: 35991712
Evidence suggests that SARS-CoV-2 viral load is an independent predictor of disease severity and mortality. A 61-year-old woman presented with severe COVID-19 and was treated with casirivimab/imdevimab and remdesivir. Quantitative...
7.
Barkauskas C, Mylonakis E, Poulakou G, Young B, Vock D, Siegel L, et al.
Ann Intern Med
. 2022 Aug;
175(9):1266-1274.
PMID: 35939810
Background: Ensovibep (MP0420) is a designed ankyrin repeat protein, a novel class of engineered proteins, under investigation as a treatment of SARS-CoV-2 infection. Objective: To investigate if ensovibep, in addition...
8.
Wolfe C, Tomashek K, Patterson T, Gomez C, Marconi V, Jain M, et al.
Lancet Respir Med
. 2022 May;
10(9):888-899.
PMID: 35617986
Background: Baricitinib and dexamethasone have randomised trials supporting their use for the treatment of patients with COVID-19. We assessed the combination of baricitinib plus remdesivir versus dexamethasone plus remdesivir in...
9.
Douin D, Siegel L, Grandits G, Phillips A, Aggarwal N, Baker J, et al.
Am J Respir Crit Care Med
. 2022 May;
206(6):730-739.
PMID: 35580040
Uncertainty regarding the natural history of coronavirus disease (COVID-19) led to difficulty in efficacy endpoint selection for therapeutic trials. Capturing outcomes that occur after hospital discharge may improve assessment of...
10.
Sloan B, Duhaime E, Sandkovsky U, Berhe M
Proc (Bayl Univ Med Cent)
. 2022 May;
35(3):339-341.
PMID: 35518791
Casirivimab/imdevimab, a cocktail of monoclonal antibodies, is currently approved for emergency use in high-risk ambulatory patients with early COVID-19 to reduce risk of hospitalization and/or death from SARS-CoV-2 infection. In...